{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-+Breast+Cancer&page=38", "query": { "condition": "HER2- Breast Cancer", "page": 38 }, "page_size": 10 }, "pagination": { "page": 38, "page_size": 10, "total_count": 1360, "total_pages": 136, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-+Breast+Cancer&page=39&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-+Breast+Cancer&page=37&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T08:25:24.138Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03709082", "title": "Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer", "Breast Cancer Metastatic" ], "interventions": [ { "name": "Palbociclib 75mg", "type": "DRUG" }, { "name": "Letrozole 2.5mg", "type": "DRUG" }, { "name": "T-DM1", "type": "DRUG" }, { "name": "Palbociclib 100mg", "type": "DRUG" }, { "name": "Palbociclib 125mg", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 3, "start_date": "2018-10-15", "completion_date": "2021-02-03", "has_results": false, "last_update_posted_date": "2024-03-05", "last_synced_at": "2026-10-30T08:25:24.138Z", "location_count": 5, "location_summary": "Kansas City, Kansas • Overland Park, Kansas • Kansas City, Missouri + 1 more", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Lee's Summit", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03709082" }, { "nct_id": "NCT07706179", "title": "Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HR+/HER2+ Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2026-11", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-10-29", "last_synced_at": "2026-10-30T08:25:24.138Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07706179" }, { "nct_id": "NCT02032823", "title": "Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 1837, "start_date": "2014-04-22", "completion_date": "2029-05-28", "has_results": true, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-10-30T08:25:24.138Z", "location_count": 368, "location_summary": "Anchorage, Alabama • Anchorage, Alaska • Gilbert, Arizona + 321 more", "locations": [ { "city": "Anchorage", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Baldwin Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02032823" }, { "nct_id": "NCT05143229", "title": "Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Alpelisib", "type": "DRUG" }, { "name": "Sacituzumab govitecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2022-03-28", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-10-30T08:25:24.138Z", "location_count": 7, "location_summary": "Fairway, Kansas • Overland Park, Kansas • Westwood, Kansas + 2 more", "locations": [ { "city": "Fairway", "state": "Kansas" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05143229" }, { "nct_id": "NCT00591851", "title": "Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 70, "start_date": "2004-12", "completion_date": "2008-06", "has_results": true, "last_update_posted_date": "2023-09-25", "last_synced_at": "2026-10-30T08:25:24.138Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00591851" }, { "nct_id": "NCT05889988", "title": "A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Neoplasm" ], "interventions": [], "intervention_types": [], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2023-06-12", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2025-11-20", "last_synced_at": "2026-10-30T08:25:24.138Z", "location_count": 21, "location_summary": "Aitkin, Minnesota • Baxter, Minnesota • Brainerd, Minnesota + 17 more", "locations": [ { "city": "Aitkin", "state": "Minnesota" }, { "city": "Baxter", "state": "Minnesota" }, { "city": "Brainerd", "state": "Minnesota" }, { "city": "Deer River", "state": "Minnesota" }, { "city": "Detroit Lakes", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05889988" }, { "nct_id": "NCT00003612", "title": "Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 92, "start_date": "1999-04", "completion_date": "2019-03-15", "has_results": false, "last_update_posted_date": "2019-10-08", "last_synced_at": "2026-10-30T08:25:24.138Z", "location_count": 24, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 20 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003612" }, { "nct_id": "NCT02780401", "title": "Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2/Neu Negative", "No Evidence of Disease", "One or More Positive Axillary Nodes", "Stage IB Breast Cancer", "Stage II Breast Cancer", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage III Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine", "type": "BIOLOGICAL" }, { "name": "Sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2016-09-02", "completion_date": "2022-10-08", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-30T08:25:24.138Z", "location_count": 2, "location_summary": "Seattle, Washington • Madison, Wisconsin", "locations": [ { "city": "Seattle", "state": "Washington" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02780401" }, { "nct_id": "NCT04351230", "title": "T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "HER2 Positive Breast Carcinoma", "Metastatic Breast Carcinoma", "Prognostic Stage IV Breast Cancer AJCC v8" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Trastuzumab Emtansine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-11-11", "completion_date": "2022-02-16", "has_results": false, "last_update_posted_date": "2022-05-26", "last_synced_at": "2026-10-30T08:25:24.138Z", "location_count": 6, "location_summary": "Yuma, Arizona • Jacksonville, Florida • Urbana, Illinois + 3 more", "locations": [ { "city": "Yuma", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04351230" }, { "nct_id": "NCT04147819", "title": "A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancers With HER2 Expression" ], "interventions": [ { "name": "BAY2701439", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2020-07-02", "completion_date": "2023-09-26", "has_results": false, "last_update_posted_date": "2024-09-27", "last_synced_at": "2026-10-30T08:25:24.138Z", "location_count": 4, "location_summary": "Baltimore, Maryland • St Louis, Missouri • New York, New York + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04147819" } ] }